When you look matters: The effect of assessment schedule on progression-free survival

被引:141
作者
Panageas, Katherine S.
Ben-Porat, Leah
Dickler, Maura N.
Chapman, Paul B.
Schrag, Deborah
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
关键词
D O I
10.1093/jnci/djk091
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Progression-free survival (PFS) is increasingly used as an endpoint for cancer clinical trials. Disease progression is typically assessed on the basis of radiologic testing at scheduled time points or after a fixed number of treatment cycles. The date of the radiologic evaluation at which progression is first evident is used as a proxy for the true progression time. The true progression time actually lies somewhere within the time interval between two assessments, a situation that results in interval-censored data. An analysis that ignores this interval censoring and uses the detection date as the date of progression unavoidably results in an overestimation of median PFS. This overestimation can erroneously result in a result being described as clinically significant when in fact a longer median PFS may just be a consequence of the length of the surveillance interval. Furthermore, if surveillance intervals are heterogenous within a disease group, comparisons of median PFS across studies may not be meaningful. The decision to use PFS as a primary endpoint should be made carefully when designing clinical trials, and investigators focused on a particular disease should develop consensus standards and strive for consistent surveillance intervals.
引用
收藏
页码:428 / 432
页数:5
相关论文
共 11 条
[1]  
Dickler M, 2004, J CLIN ONCOL, V22, p127S
[2]  
Groeneboom P., 1992, INFORM BOUNDS NONPAR
[3]   End points and United States food and drug administration approval of oncology drugs [J].
Johnson, JR ;
Williams, G ;
Pazdur, R .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (07) :1404-1411
[4]   Addition of bevacizurnab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial [J].
Kabbinavar, FF ;
Schulz, J ;
McCleod, M ;
Patel, T ;
Hamm, JT ;
Hecht, JR ;
Mass, R ;
Perrou, B ;
Nelson, B ;
Novotny, WF .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3697-3705
[5]  
Lindsey JC, 1998, STAT MED, V17, P219, DOI 10.1002/(SICI)1097-0258(19980130)17:2<219::AID-SIM735>3.0.CO
[6]  
2-O
[7]   MAXIMUM-LIKELIHOOD-ESTIMATION FOR INTERVAL-CENSORED DATA USING A WEIBULL-BASED ACCELERATED FAILURE TIME MODEL [J].
ODELL, PM ;
ANDERSON, KM ;
DAGOSTINO, RB .
BIOMETRICS, 1992, 48 (03) :951-959
[8]  
PETO R, 1973, J R STAT SOC C-APPL, V22, P86
[9]  
*SAS I INC, 1993, ICE MACR COMP NONP S
[10]  
Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205